Key Takeaway
This liraglutide Saxenda guide covers everything you need to know about one of the original GLP-1 medications approved for weight management. Liraglutide was a big deal when it launched. But the GLP-1 environment has evolved.
This liraglutide Saxenda guide covers everything you need to know about one of the original GLP-1 medications approved for weight management. Liraglutide was a big deal when it launched. But the GLP-1 environment has evolved. Today, weekly injection options offer more convenience and often stronger results. So where does liraglutide fit in now?
Key Takeaways: - Learn how liraglutide works - Efficacy: How Much Weight Loss to Expect - Cost Comparison and Access - Who Is Liraglutide Best For
Let's walk through how it works, what to expect, and who it might still be right for.
How Liraglutide Works
Liraglutide is a GLP-1 receptor agonist. It mimics a natural hormone your gut produces after eating. This hormone tells your brain you are full, slows stomach emptying, and helps regulate blood sugar.
The medication is available under two brand names. Victoza is approved for type 2 diabetes at doses up to 1.8 mg daily. Saxenda is approved for weight management at a higher dose of 3.0 mg daily.
"We now have cardiovascular outcomes data showing semaglutide reduces MACE events by 20% in people with obesity, independent of diabetes status. The SELECT trial changed how we think about these medications.") Dr. A. Michael Lincoff, MD, Cleveland Clinic, lead author of SELECT
Unlike newer GLP-1 medications that you inject once per week, liraglutide requires a daily injection. You inject it under the skin in your stomach, thigh, or upper arm at the same time each day.
The dosing starts low and increases gradually. Most people begin at 0.6 mg daily and increase by 0.6 mg each week until reaching the target dose. This titration schedule helps your body adjust and reduces side effects.
For a broader look at how GLP-1 medications work, check out our .
Efficacy: How Much Weight Loss to Expect
Clinical trials showed that liraglutide 3.0 mg produced an average weight loss of about 8% of body weight over 56 weeks. That is meaningful, but it is lower than what studies show for newer options.
Free Download: GLP-1 Medication Comparison One-Pager Compare liraglutide head-to-head with semaglutide, tirzepatide, and other GLP-1 options. Get yours free (we'll email it to you instantly. [Email Input] [Download Button]
For comparison, semaglutide 2.4 mg (weekly) showed about 15% weight loss in trials. Tirzepatide showed up to 22%. So liraglutide typically produces roughly half the weight loss of semaglutide.
However, averages can be misleading. Some people respond very well to liraglutide. Others may not respond as strongly. Individual results depend on factors like diet, exercise, starting weight, and genetics.
Liraglutide also has strong cardiovascular safety data. The LEADER trial (Marso et al., NEJM, 2016) showed it reduced major cardiovascular events in people with type 2 diabetes by 13%. That heart benefit matters, especially for people with existing cardiovascular risk.
Cost Comparison and Access
One of the biggest considerations with liraglutide is cost. The brand-name versions can cost over $1,000 per month without insurance. Some insurance plans cover it, especially for diabetes, but coverage for weight management varies.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →Here is where things get interesting. Because liraglutide has been on the market longer, generic versions are starting to become available in some markets. This could make it more affordable over time.
If cost is a major factor in your decision, compounded semaglutide through FormBlends may offer a more cost-effective path with stronger weight loss results. Our providers can walk you through all your options.
For a detailed cost breakdown across GLP-1 options, visit our .
Who Is Liraglutide Best For?
Liraglutide may still be a good fit for certain people. If you prefer more control over your dosing with daily adjustments, a daily injection gives you that flexibility. Some people find it easier to manage side effects when they can fine-tune their dose day by day.
It is also an established option with years of safety data. The FDA approved Saxenda in 2014, so there is a long track record of real-world use.
People who have tried weekly GLP-1 options and experienced strong side effects might find the shorter-acting nature of liraglutide more manageable. Because it clears your system faster, any side effects tend to resolve more quickly.
That said, for most people starting GLP-1 treatment today, weekly options tend to be the preferred choice. They offer more convenience and generally stronger results.
Frequently Asked Questions
How often do you inject liraglutide?
Liraglutide requires one injection per day, given at roughly the same time each day. You inject it under the skin in your stomach, thigh, or upper arm. This is different from weekly GLP-1 medications like semaglutide.
Is liraglutide as effective as semaglutide?
Studies suggest semaglutide produces roughly twice the weight loss of liraglutide. Liraglutide averages about 8% body weight loss, while semaglutide averages about 15%. However, individual results vary. Read our for more details.
What are the common side effects of liraglutide?
The most common side effects include nausea, vomiting, diarrhea, and constipation. These usually improve during the first few weeks. The gradual dose increase helps minimize these effects. Check our for management tips.
Can I switch from liraglutide to semaglutide?
Yes, many people transition from liraglutide to semaglutide under the guidance of their provider. A licensed provider can help you make the switch safely, adjusting your dose and monitoring your response.
What's Your Next Move?
You have the information. Now let a licensed provider help you put it into action. FormBlends makes it simple, answer a few questions and get a personalized recommendation.
Sources & References
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. Doi:10.1056/NEJMoa1411892
- Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. Doi:10.1056/NEJMoa1603827
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2 (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3 (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4 (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881
The information in this article is intended for educational use only and should not be considered medical advice. Consult a qualified healthcare provider before making any changes to your medication or supplement regimen. FormBlends helps with connections with licensed providers for personalized medical guidance.
Last updated: 2026-03-24